Zhejiang Shapuaisi Pharmaceutical Co. Ltd. Class A

Zhejiang Shapuaisi Pharmaceutical Co. Ltd. Class A

SSSE:603168
4.88
CNY
-0.15
(-2.98%)
-0.89EPS
2.25BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.81
2.95
3.11
3.3
2.89
1.87
1.31
1.12
1.94
1.72
1.78
1.29
1.24
1.1
Basic EPS, GAAP
0.47
0.51
0.59
0.93
0.45
-0.39
0.02
-0.56
0.11
0.14
0.07
-0.33
-0.64
-0.89
Free Cash Flow per Basic Share
0.21
0.18
0.06
0.86
-0.21
0.13
0.1
0.08
-0.16
-0.1
-0.49
-0.27
-0.13
- -
Dividend per Share
0.16
0.13
0.16
0.2
0.26
0.15
- -
0.01
- -
- -
0.04
0.04
0.02
0.02
Book Value per Share
1.58
2.57
3
4.94
5.14
4.59
4.62
4.05
4.19
4.58
4.54
4.23
3.61
3.45
Tangible Book Value per Share
1.44
2.46
2.02
4.05
4.41
4.38
4.46
2.46
2.64
3.27
3.09
2.77
2.62
2.45
Basic Weighted Avg Shares
223
260
297
296
325
324
393
320
324
320
363
374
373
373
Sales/Revenue/Turnover
628
766
922
979
939
607
516
358
630
550
645
484
463
409
Operating Margin (%)
19.71
20.01
22.21
24.53
23.49
6.95
1.61
-25.86
7.5
8.59
3.05
-10.81
-1.32
-14.2
Depreciation Expense
13
25
28
43
50
53
56
65
62
66
73
73
71
- -
Net Income, GAAP
104
131
176
276
146
-126
8
-179
36
45
25
-123
-239
-332
Effective Tax Rate (%)
13.88
13.88
15.63
14.14
21.64
- -
53.18
- -
27.04
17.14
24.11
- -
- -
- -
Profit Margin (%)
16.57
17.15
19.1
28.17
15.59
-20.82
1.52
-50.07
5.66
8.14
3.94
-25.51
-51.58
-81.16
Working Capital
140
390
121
695
745
747
834
286
359
522
185
-11
-23
-76
LT Debt
69
- -
50
- -
- -
- -
- -
8
38
34
71
137
123
88
Total Equity
353
763
892
1,594
1,657
1,481
1,489
1,306
1,352
1,715
1,729
1,590
1,351
1,286
Return on Invested Capital (%)
20.53
19.46
20.2
15.61
8.42
- -
-0.36
- -
2.92
2.91
0.91
- -
- -
- -
Return on Capital (%)
22.14
21.05
20.66
22.13
9
- -
0.53
- -
2.68
2.93
1.51
- -
- -
- -
Return on Common Equity (%)
33.17
23.52
21.28
22.18
9
-8.06
0.53
-12.83
2.68
2.93
1.48
-7.46
-16.24
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
146
210
215
LT Borrowings
108
63
82
LT Finance Leases
13
6
5
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
374
374
373
Market Capitalization
2,638
1,766
2,250

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
284
330
289
Cash, Cash Equivalents & STI
121
204
150
Accounts Receivable, Net
27
25
30
Inventories
88
73
75
Total Current Liabilities
318
353
365
Payables & Accruals
- -
- -
- -
ST Debt
146
210
215
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.85%
1.62%
-15%
Free Cash Flow
114.42%
2.66%
-51.95%
Net Income, GAAP
-329.58%
-126.01%
93.39%
Sales/Revenue/Turnover
-2.77%
10.22%
-4.38%
Total Cash Common Dividend
- -
- -
-45.35%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
138
99
123
125
484
2025
102
134
- -
112
463
2026
99
98
100
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
-0.08
-0.02
-0.25
-0.33
2025
0.02
0.03
- -
-0.72
-0.64
2026
-0.07
0.12
-0.23
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.03
- -
- -
0.04
2025
- -
0.01
- -
- -
0.02
2026
- -
0.01
0.01
- -
- -

Company Description

CEO
Hong Li Lin
Full Time Employees
1,142
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 1588 Xinming Road Pinghu ZH China 314200
IPO Date
Jun 19, 2014
Website
zjspas.com
Business
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. is a China-based pharmaceutical company principally engaged in the research and development, production, and sale of pharmaceutical products. The company offers a comprehensive portfolio including antibiotics, ophthalmology drugs, gynecology products, antipyretic and analgesics, antibacterial and anti-inflammatory drugs, endocrine-related therapies, cardiovascular medications, detoxification products, diuretics, and infusion solutions. These products are available in various forms such as injections, oral solutions, eye drops, tablets, and capsules. Zhejiang Shapuaisi serves primarily the domestic Chinese market with a focus on conditions including blepharitis, meibomian gland inflammation, conjunctivitis, keratitis, and other ocular diseases, as well as broad anti-infective and systemic treatments. Founded in 1978 and headquartered in Pinghu, Zhejiang Province, the company has developed a strong R&D and manufacturing capability, maintaining a leading position in several therapeutic segments. It was successfully listed on the Shanghai Stock Exchange in 2014. Recent key operational changes include the approval and launch of new ophthalmic products such as levofloxacin eye drops and polyvinyl alcohol eye drops, which are used for treating various eye infections and dry eye symptoms. In 2024, Zhejiang Shapuaisi strategically divested its wholly-owned pharmacy chain subsidiary to focus on its core pharmaceutical manufacturing business. The company has not engaged in major mergers or acquisitions recently but continues to emphasize internal growth and product innovation to strengthen its market presence. Zhejiang Shapuaisi Pharmaceutical's business segments cover research, manufacturing, and sales across multiple therapeutic areas including antimicrobial, ophthalmic, gynecological, cardiovascular, and anti-inflammatory sectors. The company targets hospitals, pharmacies, and healthcare providers within China, offering a broad product range designed to address both common and specialized medical conditions. Its drug pipeline and product approvals reflect ongoing efforts to expand its ophthalmic and anti-infective offerings supported by regulatory endorsements from China's National Medical Products Administration. This focus positions Zhejiang Shapuaisi as a comprehensive pharmaceutical provider with diversified product lines and a regional market footprint centered in China.